May 2011 Archives - Silence Therapeutics

News	Events
Publications	Companies
Clinical Trials

ASCO confab gives Alnylam, RNAi a shot to shine
0 Replies

May 27, 2011

Stories include: Alnylam Pharmaceuticals ($ALNY) appears to looking at the annual ASCO confab--the industry's biggest cancer drug meeting--as a key stage to boost the appeal of its gene-silencing or RNAi technology. The company's move comes after a year that saw some Big Pharma companies scale back research in the field.... Contine Reading & Discuss→

Posted in News

Inspire joins AzaSite lawsuit; Pharmascience buys Aegera
0 Replies

May 26, 2011

Stories include: @FiercePharma: Amylin wins TRO in fight over Lilly marketing pact. News InSite Vision is joining Merck and Pfizer in filing a patent infringement lawsuit against Sandoz, which recently filed an Abbreviated New Drug Application with the FDA seeking to market a generic version of AzaSite (azithromycin 1 percent... Contine Reading & Discuss→

Posted in News

Holding in Company
0 Replies

May 25, 2011

Contine Reading & Discuss→

Posted in News and Events

Holding in Company
0 Replies

May 20, 2011

Contine Reading & Discuss→

Posted in News and Events

Holding in Company
0 Replies

May 19, 2011

Contine Reading & Discuss→

Posted in News and Events

RXi Pharmaceuticals Presents Updated NeuVax™ (E75) Data At ASCO
0 Replies

WORCESTER, Mass., May 19, 2011 (BUSINESS WIRE) — RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted and immunotherapy technologies, will be presenting data from the NeuVax™ (E75) Phase II adjuvant breast cancer clinical trial at... Contine Reading & Discuss→

Posted in News

Holding in Company
0 Replies

May 18, 2011

Contine Reading & Discuss→

Posted in News and Events

Publication of 2010 Annual Report and Notice of AGM
0 Replies

Contine Reading & Discuss→

Posted in News and Events

Silence Therapeutics to Present New Data from Phase I Study with Atu027 at 2011 ASCO Annual Meeting
0 Replies

Contine Reading & Discuss→

Posted in News and Events

Mauro Ferrari Honored by the Controlled Release Society
0 Replies

May 17, 2011

HOUSTON (May 17, 2011) - Mauro Ferrari, Ph.D. , president and CEO of The Methodist Hospital Research Institute in Houston, recently received the 2011 CRS Founders' Award. The prestigious, internationally-recognized Founders Award honors outstanding leaders in the field of bioactive material delivery science. Contine Reading & Discuss→

Posted in Companies | Tagged in | Arrowhead Research Corporation Posted in News | Tagged in | Arrowhead Research Corporation Posted in Other News | Tagged in | Arrowhead Research Corporation Posted in Syndicated | Tagged in | Arrowhead Research Corporation